Observational study on classic infectious diseases

Real World Study of Classic Infectious Disease

This study looks at samples from patients with classic infectious diseases like brucellosis and kala-azar in China to see how common they are and what treatments work best.

Quick facts

• Study type: Observational
• Enrollment: 10000 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Huashan Hospital (Academic / other)
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT04020536 on ClinicalTrials.gov

What this trial studies

This study collects and analyzes clinical specimens from patients diagnosed with classic infectious diseases such as brucellosis, epidemic hemorrhagic fever, and kala-azar. It aims to investigate the epidemiological distribution and treatment options for these diseases in China. The study focuses on real-world data to understand the current trends and challenges associated with these infections. By examining patient samples and clinical data, the research seeks to provide insights into effective management strategies for these conditions.

Who should consider this trial

Good fit: Ideal candidates for this study include patients with confirmed cases of brucellosis, epidemic hemorrhagic fever, or kala-azar.

Not a fit: Patients with incomplete medical history, HIV positive status, or those who are pregnant or lactating may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the understanding and treatment of classic infectious diseases in China, leading to improved patient outcomes.

How similar studies have performed: Other studies have shown success in understanding infectious diseases through real-world data collection, making this approach both relevant and potentially impactful.

Eligibility criteria

Inclusion Criteria:

Brucellosis： Patients with any of the following confirmed the evidence.

1. sample culture: Brucella;
2. Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever：

1 specific antibody positive 2 Hantavirus RNA positive kala-azar：

1. latent infection: rK39 antibody positive
2. patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)

Exclusion Criteria:

1. Patient history data is incomplete
2. HIV antibody positive and AIDS patients
3. Patients who participated in other clinical trials during the same period.
4. Pregnant, lactating women or women of childbearing age who are ready to conceive.

Where this trial is running

Shanghai, Shanghai Municipality

• Huashan Hospital of Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: JingWen Ai, Doctor

Conditions Brucelloses; Epidemic Hemorrhagic Fever; Kala-Azar; real world study